GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (NAS:EYPT) » Definitions » Cyclically Adjusted Book per Share

EyePoint Pharmaceuticals (EyePoint Pharmaceuticals) Cyclically Adjusted Book per Share : $4.96 (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is EyePoint Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

EyePoint Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2024 was $5.010. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.96 for the trailing ten years ended in Mar. 2024.

During the past 12 months, EyePoint Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -2.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -7.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -12.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -51.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of EyePoint Pharmaceuticals was -7.80% per year. The lowest was -80.30% per year. And the median was -21.00% per year.

As of today (2024-05-20), EyePoint Pharmaceuticals's current stock price is $12.005. EyePoint Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $4.96. EyePoint Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 2.42.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of EyePoint Pharmaceuticals was 5.82. The lowest was 0.02. And the median was 0.77.


EyePoint Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for EyePoint Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Cyclically Adjusted Book per Share Chart

EyePoint Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.71 6.31 5.24 5.11 4.95

EyePoint Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.09 5.08 4.99 4.95 4.96

Competitive Comparison of EyePoint Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EyePoint Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



EyePoint Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, EyePoint Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.01/131.7762*131.7762
=5.010

Current CPI (Mar. 2024) = 131.7762.

EyePoint Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 5.094 100.560 6.675
201409 12.203 100.428 16.012
201412 10.973 99.070 14.596
201503 9.468 99.621 12.524
201506 7.945 100.684 10.399
201509 6.399 100.392 8.399
201512 4.868 99.792 6.428
201603 7.791 100.470 10.219
201606 6.110 101.688 7.918
201609 4.227 101.861 5.468
201612 4.319 101.863 5.587
201703 3.507 102.862 4.493
201706 3.388 103.349 4.320
201709 2.239 104.136 2.833
201712 2.189 104.011 2.773
201803 1.521 105.290 1.904
201806 1.568 106.317 1.943
201809 5.038 106.507 6.233
201812 0.000 105.998 0.000
201903 2.080 107.251 2.556
201906 2.654 108.070 3.236
201909 1.475 108.329 1.794
201912 0.761 108.420 0.925
202003 1.321 108.902 1.598
202006 0.335 108.767 0.406
202009 0.578 109.815 0.694
202012 1.022 109.897 1.225
202103 4.026 111.754 4.747
202106 3.717 114.631 4.273
202109 3.224 115.734 3.671
202112 5.438 117.630 6.092
202203 4.900 121.301 5.323
202206 4.445 125.017 4.685
202209 4.002 125.227 4.211
202212 2.827 125.222 2.975
202303 2.285 127.348 2.364
202306 1.669 128.729 1.709
202309 1.660 129.860 1.685
202312 5.430 129.419 5.529
202403 5.010 131.776 5.010

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


EyePoint Pharmaceuticals  (NAS:EYPT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

EyePoint Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=12.005/4.96
=2.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of EyePoint Pharmaceuticals was 5.82. The lowest was 0.02. And the median was 0.77.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


EyePoint Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


EyePoint Pharmaceuticals (EyePoint Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Executives
Ye Liu director ROOM 502-I, WANT WANT PLAZA, NO. 211 SHIMEN YI ROAD, SHANGHAI F4 200041
Dario A. Paggiarino officer: Chief Medical Officer 4025 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
Michael Craig Pine officer: Chief Corp Dev.&Strat. Officer C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, SUITE A-210, WATERTOWN MA 02472
Nancy Lurker director, officer: President and CEO PDI, INC., 1 ROUTE 17 SOUTH, SADDLE RIVER NJ 07458
Stuart Duty director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Ew Healthcare Partners, L.p. 10 percent owner 21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Karen L. Zaderej director AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Anthony P Adamis director 3 TIMES SQUARE, 12TH FLOOR, NEW YORK NY 10036
Therapeutics Ocumension 10 percent owner 56F, ONE MUSEUM PLACE, 669 XIN ZHA ROAD, JING'AN DISTRICT, SHANGHAI F4 200041
George Elston officer: Chief Financial Officer 124 CHATHAM STREET, CHATHAM NJ 07928
Wendy F Dicicco director
David Scott Jones officer: SVP & Chief Commercial Officer C/O EYEPOINT PHARMACEUTICALS, INC.,, 480 PLEASANT STREET, SUITE A210, WATERTOWN MA 02472
John B. Landis director 1700 KENT AVENUE, WEST LAFAYETTE IN 46906
Jay S. Duker director C/O ELEVEN BIOTHERAPEUTICS, 215 1ST ST. #400, CAMBRIDGE MA 02142
Douglas Evan Godshall director SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000

EyePoint Pharmaceuticals (EyePoint Pharmaceuticals) Headlines

From GuruFocus